Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report

Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report

Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of...

Full description

Bibliographic Details
Main Authors:	Midori Hara, Satoru Kira, Manabu Kamiyama, Tatsuya Ihara, Takeshi Sato, Takahiko Mitsui
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Urology Case Reports
Subjects:	Neuroendocrine prostate cancer Tumor mutational burden high Peptide receptor radionuclide therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S221444202200170X

Similar Items

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice
by: Mei-Fang Cheng, et al.
Published: (2024-06-01)

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
by: Elena María Vida Navas, et al.
Published: (2021-04-01)

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms
by: Emma Boehm, et al.
Published: (2024-11-01)

Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT
by: Jose E Nunez, et al.
Published: (2024-07-01)

Neuroendocrine differentiation in prostate cancer – a review
by: R. Popescu, et al.
Published: (2015-12-01)

Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
by: Anke Kröcher, et al.
Published: (2023-10-01)

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
by: Paul M. D. Gape, et al.
Published: (2024-03-01)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
by: Amit Kumar, et al.
Published: (2022-06-01)

Neuroendocrine aspects of prostate oncogenesis
by: P.V. Glybochko, et al.
Published: (2010-03-01)

Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease
by: Espen Thiis-Evensen, et al.
Published: (2020-05-01)

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
by: Lina Merkens, et al.
Published: (2022-02-01)

Mixed adenocarcinoma and neuroendocrine prostate cancer: a case report
by: Rittu Hingorani, et al.
Published: (2014-11-01)

Small cell-like change in prostatic adenocarcinoma and intraductallesions – neuroendocrine or not?
by: Daniel Abensur Athanazio, et al.
Published: (2022-03-01)

Prostate Cancer Theranostics - An Overview
by: Diane Abou, et al.
Published: (2020-06-01)

Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis
by: Junru Chen, et al.
Published: (2023-05-01)

Primary mosaic neuroendocrine/adenocarcinoma of the prostate
by: Kálmán Almási, et al.
Published: (2024-07-01)

Gross Findings of Widespread Visceral Metastasis of Prostatic Adenocarcinoma With Neuroendocrine Features: A Case Report
by: David J. Habibian, et al.
Published: (2016-09-01)

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches
by: Andrea Lania, et al.
Published: (2021-07-01)

Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review
by: Mohammad Abufaraj, et al.
Published: (2024-03-01)

Primary large-cell neuroendocrine carcinoma of the prostate
by: Spasimir T. SHOPOV
Published: (2022-03-01)

Endocrine and paracrine characteristics of neuroendocrine prostate cancer
by: Tarana Arman, et al.
Published: (2022-11-01)

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
by: Philip E. Harris, et al.
Published: (2022-10-01)

Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients
by: Hao Zhang, et al.
Published: (2024-09-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
by: Sheila D. Rustgi, et al.
Published: (2021-05-01)

Prostate carcinoma with neuroendocrine differentiation successfully treated by early detection with imaging examination
by: Momoko Kobayashi, et al.
Published: (2020-11-01)

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer
by: Zoe R. Maylin, et al.
Published: (2024-12-01)

Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin
by: Masanori Ishizaki, et al.
Published: (2024-11-01)

Efficacy of <sup>177</sup>Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study
by: Golmehr Sistani, et al.
Published: (2020-12-01)

A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy
by: Taku Naiki, et al.
Published: (2022-11-01)

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
by: Zheng Wang, et al.
Published: (2020-01-01)

A bibliometric study of the top 100 most-cited papers in neuroendocrine prostate cancer
by: Yu Gan, et al.
Published: (2023-03-01)

Mechanisms of castration resistant prostate cancer formation and progression through neuroendocrine differentiation
by: Xueping Ma, et al.
Published: (2021-09-01)

A systematic review of primary large cell neuroendocrine carcinoma of the prostate
by: Ngan Nguyen, et al.
Published: (2024-03-01)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
by: Nai-Wen Kang, et al.
Published: (2021-11-01)

Prognostic significance of focal neuroendocrine differentiation in prostate cancer: Cases with autopsy-verified cause of death
by: M Tarjan
Published: (2010-01-01)

Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer
by: Tyrillshall S. T. Damiana, et al.
Published: (2021-05-01)

Glucose Metabolism Modification Induced by Radioligand Therapy with [<sup>177</sup>Lu]Lu/[<sup>90</sup>Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
by: Luca Urso, et al.
Published: (2022-09-01)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
by: Yuheng Hu, et al.
Published: (2021-05-01)

Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors
by: Sabah Iqbal, et al.
Published: (2024-05-01)

Neuroendocrine cancer of the prostate. Two case reports
by: Tamás Kullmann, et al.
Published: (2022-03-01)